Orthocell Chairman, John Van Der Wielen spoke with ausbiz host Nadine Blayney about the Company’s expansion into Canada with dental bone regeneration product, Striate+, and Orthocell’s strong outlook for revenue growth.
Here’s an excerpt:
“In seven quarters, we’ve had 9% CAGR up quarter on quarter, and we don’t expect that to slow down. In fact, we expect it to increase as we bring on new regulatory approvals. And what we’ve just proven with Canada, it was about eight weeks until we got our first sale, so we expect the exponential growth now to speed up.”
Take a look: